The effect of bone marrow‐ and adipose tissue‐derived mesenchymal stem cell transplantation on myocardial remodelling in the rat model of ischaemic heart failure

Abstract

This study aimed to investigate the effect of bone marrow- and adipose tissue-derived mesenchymal stem cell (BM-MSC and AD-MSC respectively) transplantation on left ventricular function and infarct area (IA) in the rat model of ischaemic heart failure. In anaesthetized Wistar rats, the left coronary artery (LCA) was occluded for 40 min with subsequent reperfusion for 7 days. Seven days following surgery, the animals with LCA occlusion/reperfusion were randomized into three groups: (i) Controls received intramyocardial injection of vehicle at three different locations within the peri-infarct zone, (ii) BM-MSC: cells were injected in the same way as in previous group (10(6) ), (iii) AD-MSC: using the same protocol as used in the BM-MSC group. In addition there was also a sham-treated group that had no injection. Two weeks following MSC transplantation, the hearts were isolated and perfused according to the Langendorff method followed by 30-min global ischaemia and 90-min reperfusion. After this IA was determined histologically. During Langendorff perfusion initial and postischaemic LV functions were the same in all groups although LV pressure at the 10th minute of reperfusion was higher in the AD-MSC group compared to controls. However, LV pressure during 30-min global ischaemia was significantly higher in BM-MSC as compared to controls and AD-MSC. The sham treated animals showed the same results as those seen with BM-MSC. Thus, BM-MSC transplantation, in contrast to transplantation of AD-MSC, resulted in better preservation of the LV ability to contract during ischaemia. Furthermore, IA was significantly smaller in BM-MSC group as compared to the controls and the AD-MSC groups. Thus this study has demonstrated that treatment with BM-MSC both ameliorates LV function and reduces histological scar size.

Sarcoplasmic Reticulum Ca-ATPase and Heart Failure 20 Years Later

“…An alternative approach obviating the need for gene therapy in the future could involve myocardial regeneration using transplantation of induced pluripotent 33 or mesenchymal stem cells, 34 or perhaps driving epicardial progenitor cells to form de novo cardiac mycoytes. 35 However, these therapies are very much in their infancy, and time will tell regarding their effectiveness in the setting of heart failure.…”

Histological and Immunohistochemical Study on the Possible Effect of Mangosteen and Mesenchymal Stem Cells on Isoproterenol Induced Myocardial Infarction in Adult Male Albino Rats

“…Group IV (Isoproterenol + MSCs): Ten rats received ISO injection as in GII. After 2 weeks, bone-marrow derived MSCs (5 x10 6 cells in 1mL of PBS) were injected into the LVW [8] via a longitudinal incision in the chest wall at the end of the sternum. The rats were sacrificed after 6 days (Subgroup IVa) and after one month (Subgroup IVb) from MSCs injection (6 weeks after ISO).…”

Non‐inferiority of microencapsulated mesenchymal stem cells to free cells in cardiac repair after myocardial infarction: A rationale for using paracrine factor(s) instead of cells

“…Cell‐based therapy of MI is considered a promising strategy for regeneration of functional myocardial tissue, resulting in prevention of postinfarction CHF . Because of their ease of isolation, rapid in vitro expansion, multipotency and immunoprivileged state, mesenchymal stem cells (MSCs) are commonly used in both experimental and clinical trials for cell therapy of MI . However, recent meta‐analyses demonstrated only a mild clinical improvement in MI patients receiving MSC transplantation, ranging from 3% to 10% increase in systolic left ventricular (LV) function in the treatment group .…”

“…| 103 KARPOV et Al. are commonly used in both experimental and clinical trials for cell therapy of MI. [4][5][6] However, recent meta-analyses demonstrated only a mild clinical improvement in MI patients receiving MSC transplantation, ranging from 3% to 10% increase in systolic left ventricular (LV) function in the treatment group. 7,8 Extremely low cell retention and engraftment in peri-infarct area have been widely recognized as the major factors limiting the effectiveness of cell-based MI therapy.…”